4 results on '"Argento, C."'
Search Results
2. Normal serum concentrations of anti-Müllerian hormone in women with regular menstrual cycles
- Author
-
Marca, A. L., Sighinolfi, G., Giulini, S., Traglia, M., Argento, C., Sala, C., Masciullo, C., Volpe, Annibale, Toniolo, D., and LA MARCA, Antonio
- Subjects
Adult ,Anti-Mullerian Hormone ,Oral ,Aging ,endocrine system ,medicine.medical_specialty ,Adolescent ,endocrine system diseases ,Cross-sectional study ,media_common.quotation_subject ,European Continental Ancestry Group ,Reproductive Endocrinology ,Normal serum ,White People ,Reference Values ,Internal medicine ,medicine ,Humans ,Ovarian reserve ,Contraceptives ,Cross-Sectional Studies ,Female ,Menstrual Cycle ,Middle Aged ,Menstrual cycle ,media_common ,biology ,urogenital system ,business.industry ,Obstetrics and Gynecology ,Anti-Müllerian hormone ,female genital diseases and pregnancy complications ,Endocrinology ,Reproductive Medicine ,Ageing ,biology.protein ,business ,hormones, hormone substitutes, and hormone antagonists ,Contraceptives, Oral ,Developmental Biology ,Hormone - Abstract
Anti-Müllerian hormone (AMH) has become the 'molecule of the moment' in the field of reproductive endocrinology. Indeed, it is valuable as a means of increasing understanding of ovarian pathophysiology and for guiding clinical management across a broad range of conditions. However, no normative values have been established for circulating AMH in healthy women. In this cross-sectional study, 277 healthy females (aged 18-50 years) were included. AMH was measured by commercial enzyme-linked immunosorbent assay. Serum AMH concentrations show a progressive decline with female ageing. The age-related changes in AMH were best fitted by a polynomial function. Mean AMH concentrations were not modified by past use of oral contraceptive and were independent of parity of women. Age-specific normative values for circulating AMH concentration were established. AMH concentrations seem to be independent of the reproductive history of the patient.
- Published
- 2010
3. Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period
- Author
-
Antonio La Marca, Maddalena Plebani, Silvano Milani, Annibale Volpe, Cindy Argento, Valentina Grisendi, Renato Seracchioli, Elena Spada, Grisendi V, Spada E, Argento C, Plebani M, Milani S, Seracchioli R, Volpe A, and La Marca A.
- Subjects
Adult ,medicine.medical_specialty ,endocrine system ,Aging ,Serum fsh ,Adolescent ,Cross-sectional study ,Endocrinology, Diabetes and Metabolism ,Estradiol ,FSH ,nomogram ,reference values ,Biological Markers ,Cross-Sectional Studies ,Female ,Follicle Stimulating Hormone, Human ,Follicular Phase ,Humans ,Italy ,Linear Models ,Luminescent Measurements ,Ovary ,Pituitary Gland, Anterior ,Premenopause ,Reference Values ,Tertiary Care Centers ,Young Adult ,Up-Regulation ,Endocrinology ,Internal medicine ,Follicular phase ,medicine ,Young adult ,business.industry ,Obstetrics and Gynecology ,Nomogram ,medicine.disease ,medicine.anatomical_structure ,Reference values ,business ,Poor ovarian reserve ,hormones, hormone substitutes, and hormone antagonists ,Biomarkers - Abstract
High serum day 3 FSH levels are associated with poor ovarian reserve and reduced fertility, but the interpretation of FSH values according to age is still not univocal. The purpose of this study was to determine age-dependent reference values in women with regular menstrual cycles and FSH as a guide for specialists. The study was performed at the Department of Mother-Infant of a University-based tertiary care centre. One-hundred ninety-two healthy normal menstruating women were recruited for the study. All patients attended the department on menstrual cycle day 3 for a blood sample for FSH and estradiol determination. A linear relationship between FSH or estradiol serum levels and age was observed. The FSH level increased by 0.11 IU for every year of age (1 IU for every 9 years of age). The values of FSH and estradiol corresponding to the 5th, 25th, 50th, 75th, 95th centiles for any specific age have been calculated. Serum FSH levels need to be interpreted according to age-dependent reference values. Serum FSH levels on 95th centile for any age may represent a warning sign for reduced ovarian reserve.
- Published
- 2014
4. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients
- Author
-
Pietro Violi, R. Malizia, Domenico Giuseppe D'Ascola, Alessia Pepe, Alberto Morabito, Saveria Campisi, Gaetano Restivo Pantalone, Maria Antonietta Romeo, Calogera Gerardi, Michele Rizzo, Alessandra Quota, Christian Gluud, Aurelio Maggio, Paolo Cianciulli, Gennaro D'Amico, Francesco Gagliardotto, Aldo Filosa, Carmelo Magnano, Crocetta Argento, Paolo Rigano, Luciano Prossomariti, Vincenzo Caruso, Carmelo Fidone, Angela Vitrano, Liana Cuccia, Marcello Capra, Pantalone, GR, Maggio, A, Vitrano, A, Capra, M, Cuccia, L, Gagliardotto, F, Filosa, A, Romeo, MA, Magnano, C, Caruso, V, Argento, C, Gerardi, C, Campisi, S, Violi, P, Malizia, R, Cianciulli, P, Rizzo, M, D'Ascola, DG, Quota, A, Prossomariti, L, Fidone, C, Rigano, P, Pepe, A, D'Amico, G, Morabito, A, and Gluud, C
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Pyridones ,Thalassemia ,Clinical Biochemistry ,Deferoxamine ,Iron Chelating Agents ,Gastroenterology ,Drug Administration Schedule ,law.invention ,chemistry.chemical_compound ,Young Adult ,Randomized controlled trial ,law ,Internal medicine ,Medicine ,Humans ,Deferiprone ,Adverse effect ,Genetics (clinical) ,Survival analysis ,business.industry ,Biochemistry (medical) ,Serum ferritin level ,beta-Thalassemia ,Hematology ,Iron chelation therapy ,medicine.disease ,Chelation Therapy ,Treatment Outcome ,chemistry ,Drug Therapy, Combination ,Female ,business ,Thalassemia, Iron overload, Iron chelation therapy, Deferiprone (L1), Deferroxamine (DFO) ,medicine.drug ,Follow-Up Studies - Abstract
In β-thalassemia major (β-TM) patients, iron chelation therapy is mandatory to reduce iron overload secondary to transfusions. Recommended first line treatment is deferoxamine (DFO) from the age of 2 and second line treatment after the age of 6 is deferiprone (L1). A multicenter randomized open-label trial was designed to assess the effectiveness of long-term alternating sequential L1-DFO versus L1 alone iron chelation therapy in β-TM patients. Deferiprone 75 mg/kg 4 days/week and DFO 50 mg/kg/day for 3 days/week was compared with L1 alone 75 mg/kg 7 days/week during 5-year follow-up. A total of 213 thalassemia patients were randomized and underwent intention-to-treat analysis. Statistically, a decrease of serum ferritin levels was significantly higher in alternating sequential L1-DFO patients compared with L1 alone patients (p = 0.005). Kaplan-Meier survival analysis for the two chelation treatments did not show statistically significant differences (log-rank test, p = 0.3145). Adverse events and costs were comparable between the groups. Alternating sequential L1-DFO treatment decreased serum ferritin concentration during a 5-year treatment by comparison to L1 alone, without significant differences of survival, adverse events or costs. These findings were confirmed in a further 21-month follow-up. These data suggest that alternating sequential L1-DFO treatment may be useful for some β-TM patients who may not be able to receive other forms of chelation treatment.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.